Radiopharmaceutical developer Navidea Biopharmaceuticals has announced its PET imaging agent NAV4694 will be the subject of several presentations at this week's German Society of Nuclear Medicine annual congress, held in Hannover from 26 to 29 March.
NAV4694 is an investigational fluorine-18-labeled beta-amyloid imaging agent currently being evaluated in late-stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer's disease, mild cognitive impairment, and other forms of neurodegenerative dementia.
On 27 March, Dr. Osama Sabri, PhD, a professor of nuclear medicine and chairman and the director of the department of nuclear medicine at the University of Leipzig in Germany, will present a talk on modern nuclear medicine methods for dementia in which NAV4694 images and results will be highlighted.
Also on 27 March, during the session on dementia, Dr. Henryk Barthel, PhD, from University Hospital Leipzig, is presenting research on the influence of white matter on the detectability of brain amyloid. The study concludes that evaluation of NAV4694 PET scans and MRI data from 20 patients showed lower white-matter uptake of NAV4694 compared with other F-18 amyloid radiotracers, meaning that white matter contribution to measurements is less and may provide better sensitivity for detecting changes within patients.
